menu

Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy 

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in to hear clinical perspectives on LDL-C management in certain patients with primary hyperlipidemia.

  • Sponsored by

  • Overview

    The FDA expanded the indication of LEQVIO® (inclisiran) in July 2023, which enabled broader use of LEQVIO in certain primary hyperlipidemia patients as an adjunct to diet and statin therapy. Dive in to learn more with Dr Matthew Budoff as he speaks with Dr Ambreen Mohamed, a noninvasive cardiologist from San Diego, California.

  • INDICATION

    LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

  • IMPORTANT SAFETY INFORMATION

    Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

    Please click here for LEQVIO full Prescribing Information.

    11/23      296914

Schedule28 Feb 2024